MARKET

ADTX

ADTX

ADiTx Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.600
-0.200
-5.26%
Pre Market: 3.410 -0.19 -5.28% 09:00 01/25 EST
OPEN
3.500
PREV CLOSE
3.800
HIGH
3.610
LOW
3.190
VOLUME
59.24K
TURNOVER
--
52 WEEK HIGH
9.58
52 WEEK LOW
1.620
MARKET CAP
19.00M
P/E (TTM)
-4.9396
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
EBR, MFGP among premarket losers
Centrais Eletricas Brasileiras (EBR) -11%. after resignation of President Wilson Ferreira due to personal reasons.Molecular Data (MKD) -8%.Optical Cable (OCC) -7%.ADiTx Therapeutics (ADTX) -6%.Steel Connect (STCN) -6%.Climate Change Crisis Real Impact
Seekingalpha · 48m ago
Adamis Pharmaceuticals, AzurRx BioPharma leads healthcare gainers; Celsion, ViewRay among major losers
Gainers: Adamis Pharmaceuticals (ADMP) +47%, AzurRx BioPharma (AZRX) +38%, 111 (YI) +27%, Obalon Therapeutics (OBLN) +17%, iBio (IBIO) +17%.Losers: Celsion CLSN -18%, ViewRay VRAY -14%, ADiTx Therapeutics (ADTX) -14%, Passage Bio PASG -11%, Corbus Pharmace...
Seekingalpha · 2d ago
IBM, GSAT among premarket losers
Senseonics Holdings (SENS) -16% after raising size of stock offering.Global Ship Lease (GSL) -14% after announcing public offering.Globalstar (GSAT) -13% after Morgan Stanley cuts to underweight on valuation.Broadwind (BWEN) -13% after guiding Q4 revenue b...
Seekingalpha · 3d ago
Mid-Day Market Update: Nasdaq Rises Over 50 Points; Dyne Therapeutics Shares Plummet
Midway through trading Thursday, the Dow traded down 0.12% to 31,150.37 while the NASDAQ rose 0.37% to 13,507.06. The S&P also fell, dropping 0.05% to 3,849.99.
Benzinga · 3d ago
Mid-Afternoon Market Update: Dow Rises 50 Points; Vinco Ventures Shares Spike Higher
Toward the end of trading Thursday, the Dow traded up 0.16% to 31,238.60 while the NASDAQ rose 0.63% to 13,541.78. The S&P also rose, gaining 0.20% to 3,859.69.
Benzinga · 3d ago
CLSN, RIOT, POLA and MARA among midday movers
Gainers: Vinco Ventures (BBIG) +312%.ADiTx Therapeutics (ADTX) +90%.Qutoutiao (QTT) +65%.Ideal Power (IPWR) +51%.BiondVax Pharmaceuticals (BVXV) +39%.Celsion (CLSN) +34%.Polar Power (POLA) +33%.Addex Therapeutics (ADXN) +28%.Pioneer Power Solutions (PPSI) ...
Seekingalpha · 3d ago
ADiTx Therapeutics, Celsion leads healthcare gainers; Obalon Therapeutics, Cancer Genetics among major losers
Gainers: ADiTx Therapeutics (ADTX) +63%, Celsion (CLSN) +58%, Genetic Technologies (GENE) +39%, Addex Therapeutics (ADXN) +26%, ThermoGenesis Holdings (THMO) +19%.Losers: Obalon Therapeutics (OBLN) -25%, Cancer Genetics (CGIX) -24%, Adamis Pharmaceuticals ...
Seekingalpha · 3d ago
DJ Aditx Therapeutics Shares Double As Release Date Set for AditxtScore Platform
Dow Jones · 3d ago
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADTX. Analyze the recent business situations of ADiTx Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Institutional Holdings
Institutions: 11
Institutional Holdings: 358.22K
% Owned: 6.79%
Shares Outstanding: 5.28M
TypeInstitutionsShares
Increased
0
0
New
11
247.76K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
Chairman/President/Chief Executive Officer/Director
Amro Albanna
Chief Financial Officer
Corinne Pankovcin
Chief Operating Officer
Rowena Albanna
Other/Director
Shahrokh Shabahang
Independent Director
Laura Anthony
Independent Director
Brian Brady
Independent Director
Namvar Kiaie
Independent Director
Jeffrey Runge
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ADTX
Aditx Therapeutics, Inc. is a pre-clinical stage, life sciences company. The Company is focused on developing technologies on improving the health of the immune system through immune reprogramming and monitoring. The Company’s immune reprogramming technology is at the pre-clinical stage and is designed to retrain the immune system to induce tolerance. The Company’s immune monitoring technology is designed to provide a personalized profile of the immune system. The Company is developing nucleic acid-based technology, Apoptotic DNA Immunotherapy (ADi) that mimics the way human body naturally induces tolerance to its tissues. The Company is developing Aditxt Immune Monitor (AiM), which provides a personalized comprehensive profile of the immune system.
More

Webull offers kinds of ADiTx Therapeutics Inc stock information, including NASDAQ:ADTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADTX stock methods without spending real money on the virtual paper trading platform.